Terns Pharmaceuticals, Inc.
TERN
주식 순위
#3571
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
주가
$52.95
마지막 동기화: 2026-05-15
시가총액
$4.77B
변동 (1일)
0.00%
변동 (1년)
529.61%
국가
US
거래 Terns Pharmaceuticals, Inc. (TERN)
카테고리
Healthcare
Terns Pharmaceuticals, Inc. (TERN)의 수익
Dec 2025 기준 수익 TTM: $-95.63M
Terns Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-95.63M입니다. 2023년에 회사는 $-89.97M의 수익을 올렸으며 이는 2022년의 수익 $-59.99M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Terns Pharmaceuticals, Inc.의 수익 기록 (2018 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $-95.63M | 7.94% |
| 2024 | $-88.59M | -1.53% |
| 2023 | $-89.97M | 49.98% |
| 2022 | $-59.99M | 20.82% |
| 2021 | $-49.65M | 70.87% |
| 2020 | $-29.06M | -57.79% |
| 2019 | $-68.84M | 280.64% |
| 2018 | $-18.09M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | -5,616.18% |
US
|
|
| $-3.09B | 3,128.20% |
US
|
|
| $-4.02B | 4,099.90% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,139.87% |
NL
|
